Method and compositions for drug discovery
OwnerCharles Pidgeoninventor
Life of this patent
Estimating the term…
Loading patent…
OwnerCharles Pidgeoninventor
Estimating the term…
A drug-binding substrate formed or identified using a drug substance having a predetermined biological activity is used to screen and identify test compounds likely to exhibit the predetermined biological activity. The potential biologically active test compounds are identified by their specific binding to the drug-binding substrates as detected by any of a wide variety of techniques using labeled or unlabeled assay components. In one embodiment a monoclonal antibody raised against a drug substance is used as a drug-binding substrate to identify and isolate test compounds in a natural product extract or a combinatorial chemical library. Preferably the monoclonal antibody is characterized by its ability to bind specifically to at least one other drug substance having the same or similar biological activity as the drug substance against which it was raised. The invention finds use inter alia in drug discovery protocols, in toxicity profiling of drug substances and in assaying commercial natural products.
A method of identifying new drug substances or lead compounds for new drug substances having a predetermined biological activity in a living species, said method comprising the steps of contacting a test solution comprising an exogenous test compound of unknown biological activity with a drug-binding substrate formed or identified using a drug substance known to exhibit the predetermined biological activity in said species and capable of specific binding to said drug substance, detecting the existence of specific binding of the test compound with the drug-binding substrate, and determining whether the specific binding test compound exhibits the predetermined biological activity.
A method for screening a test compound or a set of test compounds for potential biological activity, said method comprising the steps of
A method for detecting potential toxicity of a new drug substance having a first biological activity, said method comprising the steps of
A method for identifying a drug-binding substrate for use in drug discovery testing, said method comprising the steps of
A method for identifying a drug-binding substrate for use in drug discovery testing, said method comprising the step of contacting potential drug-binding substrates with a solution comprising a plurality of drug substances, each having a common biological activity deriving from specific binding to one or more related endogenous molecules, and identifying those substrates which specifically bind to more than one of said drug substances.
A composition for analysis or screening of compounds for potential biological activity, said composition comprising at least first and second drug-binding substrates, said first substrate exhibiting a specific binding affinity to a first drug substance having a known biological activity deriving from its specific binding to one or more related endogenous molecules and said second drug-binding substrate exhibiting specific binding affinity to the same drug substance or to another drug substance having the same or similar biological activity as the first drug substance.
A method for screening a set of exogenous test compounds for potential biological activity, said method comprising the steps of
A method for screening a set of test compounds for potential biological activity, said method comprising the steps of contacting a solution of the set of test compounds or a subset thereof with a substrate comprising an antibody, a phage display library or a molecularly imprinted polymer exhibiting specific binding affinity for a control compound known to exhibit specific affinity for a biologically functional molecule, said contacting step being carried out under conditions conducive to specific binding between the substrate and any test compounds to which it specifically binds to form one or more complexes of the substrate and the respective test compounds, separating the substrate-test compound complex from at least a portion of the solution, identifying a complexed test compound, and measuring the affinity of the complexed test compound for the biologically functional molecule.
A complex useful for predicting biological activity of a test compound not known to exhibit said biological activity or to exhibit specific binding to an endogenous molecule associated with said biological activity, said complex comprising said test compound specifically bound to a substrate known to exhibit specific binding affinity for a drug substance known to exhibit said biological activity.
An apparatus for screening test compounds for biological activity, said apparatus comprising a solid substrate exhibiting specific binding affinity for a control compound having known biological activity;
A kit for analysis or screening of test compounds for potential biological activity, said kit comprising at least first and second monoclonal antibodies, said first monoclonal antibody being raised against a first drug substance having a biological activity, and said second monoclonal antibody being raised against either said first drug substance or a second drug substance having said same biological activity, and wherein said monoclonal antibodies exhibit specific binding to a drug substance other than the drug substances against which each of said monoclonal antibodies was raised.
A kit for analysis or screening of test compounds for potential biological activity, said kit comprising at least first and second monoclonal antibodies, said first monoclonal antibody being raised against a first drug substance having a predetermined biological activity and said second monoclonal antibody being raised against another drug substance having the same or a different biological activity.
A method of using a monoclonal antibody for screening test compounds of unknown biological activity for a probable biological activity, said method comprising the steps of selecting a monoclonal antibody raised against a drug substance exhibiting said biological activity and capable of specific binding to said drug substance and at least one other drug substance known to exhibit said biological activity,
A method for screening a set of exogenous test compounds of unknown biological activity for potential biological activity, said method comprising the steps of selecting a drug-binding substrate exhibiting specific affinity for a drug substance having said biological activity known to derive from specific binding to one or more related endogenous molecules;
In a method for detection or analysis of specific binding affinity between an endogenous compound known to mediate a biological function, or a derivative or analog thereof, and one or more test compounds in a set of test compounds comprising potential drug substances to identify those test compounds having potential biological activity deriving from specific binding to said endogenous molecule, wherein such method the endogenous compounds or a derivative or analog. thereof is labeled with a detectable label and subjected to capillary electrophoresis in the presence of one or more test compounds, the improvement comprising the step of substituting at least one monoclonal antibody for said endogenous compound or derivative or analog thereof, said monoclonal antibody being selected from those monoclonal antibodies that specifically bind to at least one drug substance known to bind specifically to said endogenous molecule to affect its biological activity and produce a therapeutic effect
An anti-drug substance antibody having a detectable label and capable of binding specifically to the drug substance against which it was raised and to at least one other drug substance having the same or similar biological activity.
In a method for screening a set of test compounds to identify those test compounds having potential biological activity, said method comprising the step of measuring or detecting the specific binding of said test compounds to a biologically functional molecule known to be associated with said biological activity or a chemically related derivative or analog thereof, the improvement comprising the step of substituting a monoclonal antibody for said biologically functional molecule, said antibody being selected for its specific binding affinity to a drug substance known to exhibit said biological activity.
Dependencies are inferred from the claim text.